Acceleron Pharma Inc. (XLRN) Social Stream
Acceleron Pharma Inc (XLRN) Price Targets From Analysts
The tables below show price targets and recommendations from analysts covering Acceleron Pharma Inc.
| Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Current Price | Upside Potential |
|---|---|---|---|---|---|
| 13 | $155 | $100 | $131.77 | $173.71 | -24.14% |
The Trend in the Analyst Price Target
Over the past 130 days, XLRN's average price target has gone up $7.6.
XLRN reports an average of 15.56% for its upside potential over the past 165 days.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Share Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2020-11-13 | 13 | 155 | 100 | 131.77 | 114.03 | 15.56% |
| 2020-11-06 | 13 | 155 | 100 | 130.92 | NA | NA% |
| 2020-10-21 | 13 | 155 | 100 | 129.85 | NA | NA% |
| 2020-10-01 | 13 | 155 | 100 | 129.69 | NA | NA% |
| 2020-09-19 | 13 | 155 | 89 | 128.85 | NA | NA% |
| 2020-08-21 | 13 | 155 | 89 | 128.85 | NA | NA% |
| 2020-08-07 | 12 | 137 | 89 | 126.67 | NA | NA% |
| 2020-07-17 | 12 | 137 | 88 | 125.25 | NA | NA% |
| 2020-07-15 | 12 | 137 | 88 | 124.00 | NA | NA% |
| 2020-07-06 | 12 | 140 | 88 | 124.17 | NA | NA% |
| 2020-07-01 | 12 | 140 | 88 | 124.58 | NA | NA% |
| 2020-06-25 | 12 | 140 | 88 | 124.58 | NA | NA% |
| 2020-06-17 | 12 | 137 | 72 | 117.58 | NA | NA% |
| 2020-06-01 | 12 | 137 | 72 | 117.58 | NA | NA% |
XLRN Broker Recommendations Summary
| Average Broker Rating | Strong Buy | Buy | Hold | Sell | Strong Sell | Analysts Issuing Recs |
|---|
The points below can provide you with additional insight regarding what the price target and recommendations metrics in the table above mean for investors.
- The upside potential (average analyst target price relative to current price) of XLRN is greater than 2.24% of Pharmaceutical Products stocks.
- XLRN has a higher average analyst price target than 94.95% of Pharmaceutical Products stocks.
- Acceleron Pharma Inc's number of analysts covering the stock is higher than 92.01% of Pharmaceutical Products stocks.
- The variance in analysts' estimates of XLRN is less than 31.9% of all US stocks.
Make investment decisions regarding XLRN using the data that counts. Try POWR Ratings for free.